Peter Brunovskis, Ph.D.
Patent Agent
Peter has over 11 years experience in patent law together with 14 years molecular biology research experience. He has prepared and prosecuted U.S. and foreign patent applications in a variety of fields including biotechnology (e.g., diagnostics, genomics, vaccines, nucleic acid and protein sequences, liposomal formulations, plant sciences, animal testing systems); medical devices (e.g., closure devices, drug-eluting devices, catheters, stents, guidewires, graft materials); personal care and hygiene products; anti-aging and cosmetic compositions; polymeric compositions; and green technologies employing hydrogen- and solar-based energy sources. He has evaluated patentability of pharmaceutical drug patents; assisted with freedom-to-operate and patentability opinions; formulated freedom-to-operate and invalidity searches; and provided due diligence support and evaluation of various patent portfolios. Peter has also provided pre-litigation and trial support in support of strategy formulation relating to infringement, validity and enforceability issues.
As a former Biotech Patent Examiner with the U.S. Patent and Trademark Office, he examined patent claims directed to therapeutic compositions and methods; in vivo and ex vivo gene therapy, stem cells, viral- and nonviral-based expression vectors, nucleic acid- and protein sequences, diagnostic methods, and transgenic animals, along with extensive commercial and internal database searching and review of prior art.
Publications
- Is an Isolated DNA Patentable? IP and Technology Developments - October 2011 (October 25, 2011)
- “Characterization of the chromosomal binding sites and dimerization partners of the viral oncoprotein Meq in Marek's disease virus-transformed T cells,” co-author, J. Virol., 77(23):12841-12851, 2003
- “Nanoparticles of compacted DNA transfect postmitotic cells,” co-author, J. Biol. Chem., 278(35):32578-32586, 2003
- “Marek’s disease virus (MDV) encodes an interleukin-8 homolog (vIL-8): characterization of the vIL-8 protein and a vIL-8 deletion mutant MDV,” co-author, J. Virol., 75:5159-5173, 2001
- “Transcriptional analysis of Marek’s disease virus glycoprotein D, I, and E genes: gD expression is undetectable in cell culture,” co-author, J. Virol., 75:2067-2075, 2001
- “Meq: An MDV-specific bZIP transactivator with transforming properties,” co-author, Curr. Top. Microbiol. Immunol., 255:245-260, 2001
- “MEQ and v-IL8: cellular genes in disguise?,” co-author, Acta Virologica, 43:94-101, 1999
- “Avian leukemias and lymphomas: interplay between retroviruses and herpesviruses,” co-author, Leukemia, 11:176-178, 1997
- “Novel DNA binding specificities of a putative herpesvirus bZIP oncoprotein,” co-author, J. Virol., 70:7161-7170, 1996
- “Retroviral insertional activation in a herpesvirus: Transcriptional activation of US genes by an integrated long terminal repeat in a Marek’s disease virus clone,” co-author, J. Virol., 70:2460-2467, 1996
- “The transcriptional activity of meq, a Marek’s disease herpesvirus bZIP protein persistently expressed in latently-infected transformed T-cells,” co-author, J. Virol., 69:4037-4044, 1995
- “Retrotransposition and herpesvirus evolution (Review),” co-author, Virus Genes 11:259-279, 1995
- “The Marek’s disease virus (MDV) unique short region: Alpaherpesvirus-homologous, fowlpox virus-homologous, and MDV-specific genes,” co-author, Virology, 206:324-338, 1995
- US Patent Numbers 6,087,127, 5,976,787, 5,866,697, 5,252,717, 5,252,716, 5,128,033 (co-inventor)
